AbCellera Announces Multi-Target Research Collaboration with Pfizer
VANCOUVER, British Columbia, 2017-01-05 15:00 CET (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Pfizer Inc. (NYSE:PFE). AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform to attempt to discover function-modulating antibodies against undisclosed membrane protein targets.
Carl Hansen, founding CEO of AbCellera, commented: “We are increasingly recognized as a leader in high-performance antibody discovery. Our platform allows us to screen natural immune repertoires with unparalleled depth to unlock the most challenging discovery programs. This partnership reinforces our commitment to offer leading-edge antibody discovery capabilities and to create value for companies by providing access to our platform. We welcome the opportunity to work closely with the innovative team at Pfizer and look forward to building a lasting relationship.”
“We are pleased to work with the team at AbCellera using their innovative antibody discovery platform,” said Will Somers, Vice President of Biomedicines Design, Pfizer. “We hope this platform can aid in our research as we look to bring novel medicines to patients, seeking to discover modulators of a transmembrane protein in a therapeutically important target class.”
Under the terms of the agreement, AbCellera will receive an upfront payment and research support, and will be eligible to receive up to approximately $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer’s development and commercialization of antibodies that may be generated under this collaboration. Further terms of the agreement are not disclosed.
About AbCellera Biologics, Inc.
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera’s lead technology is a proprietary single cell antibody discovery platform that provides pharmaceutical and biotechnology partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans.
Multi-year collaboration aims to generate lead antibody candidates against membrane targets using AbCellera's mAb discovery platform.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Shyft Network21.6.2018 20:20 | pressemeddelelse
Shyft Unveils Board of Advisors Comprised of Top Crypto, Industry, and Regulatory Leaders United to Redefine Identity, Regulatory Compliance and Privacy For All
VITEC21.6.2018 19:02 | pressemeddelelse
United Shore Selects VITEC's EZ TV IPTV & Digital Signage Platform for New Headquarters
SEMAFO Inc.21.6.2018 17:25 | pressemeddelelse
SEMAFO Announces Retirement of VP, Exploration & Mine Geology; Announces Geology Team Succession
Bombardier Transportation20.6.2018 11:54 | pressemeddelelse
Bombardier's Chinese Joint Venture Wins Contract to Provide an INNOVIA Automated People Mover System to Shenzhen Airport
Erytech Pharma S.A.20.6.2018 07:32 | pressemeddelelse
ERYTECH to Present at JMP Securities Life Science Conference
Crown Bioscience Inc.19.6.2018 14:01 | pressemeddelelse
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum